Introduction
Methods
Recruitment and study design
Registry data management and follow-up
Definition of complications
Supraventricular tachycardia ablation procedure
Statistical analysis
Results
Patient characteristics
Patients with SHD n = 4664 | Patients without SHD n = 7872 | p value | |
---|---|---|---|
Age* (years), mean ± SD | 66.3 ± 10.4 | 55.8 ± 14.8 | < 0.001 |
Age > 75 years, % | 17.1 | 5.0 | < 0.001 |
Male, % | 74.3 | 54.4 | < 0.001 |
Antiarrhythmic drug failure, % | 72.0 | 54.3 | < 0.001 |
Cardiac disease | |||
Coronary artery disease, % | 53.3 | 0 | < 0.001 |
Prior myocardial infarction, % | 14 | 0 | < 0.001 |
Cardiomyopathy, % | 10.4 | 0 | < 0.001 |
Hypertrophic cardiomyopathy, % | 15.8 | 0 | |
Dilative cardiomyopathy, % | 84.2 | 0 | |
Hypertensive heart disease, % | 31.8 | 0 | < 0.001 |
Valvular heart disease, % | 20.8 | 0 | < 0.001 |
Comorbidities | |||
Diabetes mellitus, % | 17.0 | 6.3 | < 0.001 |
Arterial hypertension*, % | 73.3 | 41.6 | < 0.001 |
Renal failure*, % | 10.7 | 1.7 | < 0.001 |
Previous stroke*, % | 4.4 | 2.8 | 0.069 |
Devices (PM, ICD,CRT), % | 15.1 | 3.1 | < 0.001 |
Left ventricular ejection fraction | < 0.001 | ||
Normal (> 50%), % | 63.7 | 94.6 | |
Mildly reduced (41–50%), % | 19.7 | 4.2 | |
Reduced (< 40%), % | 16.6 | 1.2 | |
CHADS2-Score*, mean ± SD | 2.8 ± 1.5 | 1.4 ± 1.2 | < 0.001 |
Oral anticoagulation, % | 41.1 | 22.2 | < 0.001 |
Procedural data and periprocedural complications
Patients with SHD n = 4664 | Patients without SHD n = 7872 | p value | |
---|---|---|---|
De novo ablation, % | 88.4 | 88.7 | 0.64 |
Procedure duration (min), median (IQR) | 100 (60; 165) | 110 (62; 170) | < 0.001 |
Fluoroscopy time (min), median (IQR) | 18 (10; 32) | 17 (8; 30) | < 0.001 |
Dose area product [(cGy)*cm2], median (IQR) | 2428 (1026; 5323) | 1771 (664; 4280) | < 0.001 |
Cumulative duration of all applications (seconds), median (IQR) | 607 (300; 1631) | 457 (166; 1615) | < 0.001 |
Death, n (%) | 4 (0.1) | 0 (0.0) | 0.019 |
MACE (death, myocardial infarction), n (%) | 4 (0.1) | 3 (0.0) | 0.44 |
MACCE (death, myocardial infarction, stroke), n (%) | 10 (0.2) | 6 (0.1) | 0.066 |
Nonfatal Stroke, n (%) | 6 (0.1) | 4 (0.1) | 0.19 |
Major bleeding (intervention), n (%) | 19 (0.4) | 27 (0.3) | 0.55 |
Transient ischemic attack, n (%) | 3 (0.1) | 3 (0.0) | 0.68 |
Cardiac tamponade, n (%) | 21 (0.5) | 35 (0.5) | 1.0 |
Aneurysm spurium, arteriovenous fistula, n (%) | 41 (0.7) | 47 (0.6) | 0.08 |
Atrio-esophageal fistula, n (%) | 0 | 0 | 0 |
Minor bleeding (without intervention), n (%) | 79 (1.7) | 108 (1.4) | 0.17 |
Duration of in-hospital stay, days | 3 (2;6) | 2 (2;4) | < 0.001 |
Arrhythmia recurrence (in-hospital), n (%) | 173 (3.7) | 279 (3.5) | 0.63 |
Follow-Up
Arrhythmia recurrence and symptoms
Patients with SHD n = 4664 | Patients without SHD n = 7872 | p value | |
---|---|---|---|
Follow-up completed, n (%) | 4555 (0.98) | 7561 (0.96) | < 0.001 |
Documented arrhythmia recurrence, n (%) | 1335 (31.4) | 2166 (29.6) | 0.044 |
Rehospitalization, n (%) | 1911 (47.4) | 2523 (36.1) | < 0.001 |
Re-ablation, n (%) | 622 (14.6) | 1023 (14.0) | 0.34 |